{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:27:02Z","timestamp":1791584822351,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.retram.2026.103568","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:16:26Z","timestamp":1770999386000},"page":"103568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unusual expression of peripheral blood Alzheimer\u2019s markers, inflammatory cytokines, and cholinergic biomarkers in chronic kidney disease patients with cognitive dysfunction: Therapeutic impact of recombinant human erythropoietin (rHuEPO)"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-6717","authenticated-orcid":false,"given":"Vinoth Kumar","family":"Ganesan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2026.103568_bib0001","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1681\/ASN.2012050536","article-title":"Cognitive disorders and dementia in CKD: the neglected kidney-brain axis","volume":"24","author":"Bugnicourt","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.retram.2026.103568_bib0002","article-title":"Hypertension primer: the essentials of high blood pressure: basic science, population science, and clinical management","author":"Izzo","year":"2007","journal-title":"Philadelphia: LippincottWilliams &Wilkins"},{"key":"10.1016\/j.retram.2026.103568_bib0003","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/01.HYP.0000168052.00426.65","article-title":"Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy","volume":"46","author":"O\u2019Rourke","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.retram.2026.103568_bib0004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol Neurodegener"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1039\/C0NP00027B","article-title":"Natural products as a source of Alzheimer's drug leads","volume":"28","author":"Williams","year":"2011","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.retram.2026.103568_bib0006","series-title":"The handbook of neuroprotection","first-page":"547","author":"Jain","year":"2011"},{"key":"10.1016\/j.retram.2026.103568_bib0007","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.3233\/JAD-2012-129025","article-title":"GSK3 and tau: two convergence points in Alzheimer\u2019s disease","volume":"33","author":"Hernandez","year":"2013","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"10.1016\/j.retram.2026.103568_bib0008","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.retram.2026.103568_bib0009","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.bbadis.2013.06.012","article-title":"Amyloid beta-induced glycogen synthase kinase 3_ phosphorylated VDAC1 in Alzheimer\u2019s disease: implications for synaptic dysfunction and neuronal damage","volume":"1832","author":"Reddy","year":"2013","journal-title":"Biochim. Biophys Acta Mol Basis Dis"},{"issue":"2","key":"10.1016\/j.retram.2026.103568_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.retram.2026.103568_bib0011","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.ajkd.2003.10.013","article-title":"Apolipoprotein E and renal disease","volume":"43","author":"Liberopoulos","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.retram.2026.103568_bib0012","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1038\/s41380-020-0688-6","article-title":"APOE\u03b54 potentiates the relationship between amyloid-\u03b2 and tau pathologies","volume":"26","author":"Therriault","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.retram.2026.103568_bib0013","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbi.2021.01.010","article-title":"Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults","volume":"94","author":"Albrecht","year":"2021","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.retram.2026.103568_bib0014","series-title":"Amyloid, tau, and apoe in alzheimer\u2019s disease: impact on white matter tracts","article-title":"Alzheimer\u2019s Disease Neuroimaging Initiative","author":"Chandio","year":"2024"},{"key":"10.1016\/j.retram.2026.103568_bib0015","article-title":"APOE mediated neuroinflammation and neurodegeneration in Alzheimer\u2019s disease","volume":"59","author":"Parhizkar","year":"2022"},{"issue":"4","key":"10.1016\/j.retram.2026.103568_bib0016","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/cells14040243","article-title":"From genetics to neuroinflammation: the impact of ApoE4 on microglial function in Alzheimer\u2019s disease","volume":"14","author":"Dias","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.retram.2026.103568_bib0017","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fimmu.2020.00754","article-title":"The important interface between apolipoprotein E and neuroinflammation in Alzheimer\u2019s disease","volume":"11","author":"Kloske","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103568_bib0018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ddr.21587","article-title":"Natural products and their derivatives as multifunctional ligands against Alzheimer\u2019s disease","volume":"81","author":"Patil","year":"2020","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.retram.2026.103568_bib0019","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnins.2019.00038","article-title":"Innovative therapy for Alzheimer\u2019s disease-with focus on biodelivery of NGF","volume":"13","author":"Mitra","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.retram.2026.103568_bib0020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1515\/revneuro-2019-0089","article-title":"Amyloid \u03b2, tau, and the cholinergic system in Alzheimer\u2019s disease: seeking direction in a tangle of clues","volume":"31","author":"Majdi","year":"2020","journal-title":"Rev Neurosci"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0021","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.kint.2022.09.022","article-title":"Association between cholinesterase inhibitors and kidney function decline in patients with Alzheimer\u2019s dementia","volume":"103","author":"Xu","year":"2023","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.retram.2026.103568_bib0022","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.kint.2019.10.032","article-title":"Crosstalk between the nervous system and the kidney","volume":"97","author":"Tanaka","year":"2020","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.retram.2026.103568_bib0023","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/ndt\/gfaa200","article-title":"The cholinergic anti-inflammatory pathway in chronic kidney disease\u2014Review and vagus nerve stimulation clinical pilot study","volume":"35","author":"Hilderman","year":"2020","journal-title":"Nephrol Dialy Transplant"},{"key":"10.1016\/j.retram.2026.103568_bib0024","first-page":"gfaf029","article-title":"Cholinergic system in patients with chronic kidney disease: cognitive and renal implications","author":"Xu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0025","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41598-020-80402-1","article-title":"Modified recombinant human erythropoietin with potentially reduced immunogenicity","volume":"11","author":"Susantad","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.retram.2026.103568_bib0026","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3389\/fphar.2018.01498","article-title":"Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: a historical perspective","volume":"9","author":"Aapro","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.retram.2026.103568_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/1759091419871420","article-title":"Erythropoietin as a neuroprotective molecule: an overview of its therapeutic potential in neurodegenerative diseases","volume":"11","author":"Rey","year":"2019","journal-title":"ASN Neuro"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0028","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nurt.2008.10.041","article-title":"Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system","volume":"6","author":"Sir\u00e9n","year":"2009","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.retram.2026.103568_bib0029","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.4103\/1673-5374.215240","article-title":"Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor","volume":"12","author":"Hern\u00e1ndez","year":"2017","journal-title":"Neural Regen Res"},{"issue":"4","key":"10.1016\/j.retram.2026.103568_bib0030","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2215\/CJN.05671207","article-title":"Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis","volume":"3","author":"McGowan","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.retram.2026.103568_bib0031","first-page":"193","article-title":"Recombinant human erythropoietin in the management of anaemia in chronic kidney disease patients-an Indian multicentre experience","volume":"7","author":"Agarwal","year":"2006","journal-title":"JIACM"},{"issue":"11","key":"10.1016\/j.retram.2026.103568_bib0032","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2215\/CJN.03470509","article-title":"A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD patients with anemia","volume":"4","author":"Pergola","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.retram.2026.103568_bib0033","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/0470846410.ch27(ii)","article-title":"Mini-mental state examination","author":"Cockrell","year":"2002","journal-title":"Principles Pract Geriat Psychiatry"},{"key":"10.1016\/j.retram.2026.103568_bib0034","series-title":"Wechsler memory scale-revised","author":"Wechsler","year":"1987"},{"issue":"5","key":"10.1016\/j.retram.2026.103568_bib0035","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.acn.2003.09.001","article-title":"The Tower of London and neuropsychological assessment of ADHD in adults","volume":"19","author":"Riccio","year":"2004","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0036","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J biol Chem"},{"issue":"6","key":"10.1016\/j.retram.2026.103568_bib0037","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/biomedicines11061606","article-title":"Exploring the link between chronic kidney disease and Alzheimer\u2019s disease: a longitudinal follow-up study using the Korean national health screening cohort","volume":"11","author":"Kwon","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0038","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2369-13-129","article-title":"Patients with chronic kidney disease are at an elevated risk of dementia: a population-based cohort study in Taiwan","volume":"13","author":"Cheng","year":"2012","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.retram.2026.103568_bib0039","first-page":"109","article-title":"Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects","volume":"15","author":"Provatopoulou","year":"2011","journal-title":"Hippokratia"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40748-015-0028-z","article-title":"Neuroprotective potential of erythropoietin in neonates; design of a randomized trial","volume":"1","author":"Juul","year":"2015","journal-title":"Matern Health Neonatol Perinatol"},{"issue":"8","key":"10.1016\/j.retram.2026.103568_bib0041","doi-asserted-by":"crossref","first-page":"e3003","DOI":"10.1038\/cddis.2017.381","article-title":"The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage","volume":"8","author":"Yoo","year":"2017","journal-title":"Cell Death Dis"},{"issue":"8","key":"10.1016\/j.retram.2026.103568_bib0042","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jocn.2013.10.040","article-title":"Neuroprotection with erythropoietin in preterm and\/or low birth weight infants","volume":"21","author":"Zhang","year":"2014","journal-title":"J Clin Neurosci"},{"issue":"6","key":"10.1016\/j.retram.2026.103568_bib0043","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1080\/13854046.2014.944937","article-title":"Single neuropsychological test scores associated with rate of cognitive decline in early Alzheimer disease","volume":"28","author":"Parikh","year":"2014","journal-title":"Clin Neuropsychol"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0044","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s43045-021-00149-x","article-title":"Evaluation of cognitive impairment in patients with major depressive disorder in remission","volume":"28","author":"Ali","year":"2021","journal-title":"Middle East Curr Psychiatry,"},{"issue":"4","key":"10.1016\/j.retram.2026.103568_bib0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/107319119800500404","article-title":"Development of the Tower of London-revised","volume":"5","author":"Schnirman","year":"1998","journal-title":"Assessment"},{"issue":"8","key":"10.1016\/j.retram.2026.103568_bib0046","first-page":"815","article-title":"The multifaceted role of platelets in mediating brain function. Blood","volume":"140","author":"Burnouf","year":"2022","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.retram.2026.103568_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120855","article-title":"Redefining oxidative stress in Alzheimer\u2019s disease: targeting platelet reactive oxygen species for novel therapeutic options","volume":"306","author":"Beura","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.retram.2026.103568_bib0048","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12035-021-02587-4","article-title":"Role of neurons and glia cells in wound healing as a novel perspective considering platelet as a conventional player","volume":"59","author":"Beura","year":"2022","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.retram.2026.103568_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101681","article-title":"Role of platelet in Parkinson\u2019s disease: insights into pathophysiology and theranostic solutions","volume":"80","author":"Beura","year":"2022","journal-title":"Ageing Res Rev"},{"issue":"3","key":"10.1016\/j.retram.2026.103568_bib0050","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00415-025-12966-9","article-title":"Tau levels in platelets isolated from Huntington\u2019s disease patients serve as a biomarker of disease severity","volume":"272","author":"Alpaugh","year":"2025","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.retram.2026.103568_bib0051","doi-asserted-by":"crossref","first-page":"fcac286","DOI":"10.1093\/braincomms\/fcac286","article-title":"Distinct brain pathologies associated with Alzheimer\u2019s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-\u03b2 amyloidosis","volume":"4","author":"Hirota","year":"2022","journal-title":"Brain Commun"},{"issue":"8","key":"10.1016\/j.retram.2026.103568_bib0052","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/biomedicines12081836","article-title":"P-tau217 as a reliable blood-based marker of Alzheimer\u2019s disease","volume":"12","author":"Lai","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.retram.2026.103568_bib0053","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Association of Plasma P-tau217 and P-tau181 with clinical phenotype, neuropathology, and imaging markers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.retram.2026.103568_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2025.149601","article-title":"Amyloidogenic and non-amyloidogenic pathways of amyloid precursor protein processing in oligodendrocytes","volume":"1855","author":"Hida","year":"2025","journal-title":"Brain Res"},{"key":"10.1016\/j.retram.2026.103568_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000539596","article-title":"Kidney amyloidosis: updates on pathogenesis and therapeutic frontiers","author":"Cervantes","year":"2024","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.retram.2026.103568_bib0056","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ckj\/sfu021","article-title":"Amyloid nephropathy","volume":"7","author":"Khalighi","year":"2014","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.retram.2026.103568_bib0057","doi-asserted-by":"crossref","DOI":"10.34172\/jnp.2022.17238","article-title":"Platelet glycogen synthase kinase 3\u03b2 regulates plasma \u03b2 amyloid and phosphorylated tau levels in chronic kidney disease patients with cognitive dysfunction; therapeutic role of erythropoietin","volume":"12","author":"Ganesan","year":"2021","journal-title":"J Nephropathol"},{"issue":"104","key":"10.1016\/j.retram.2026.103568_bib67","first-page":"211","article-title":"Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and A\u03b2 expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer\u2019s disease: A pilot study","author":"Vinothkumar","year":"2018","journal-title":"Biomed Pharma Biomed"},{"key":"10.1016\/j.retram.2026.103568_bib0058","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jocn.2019.08.073","article-title":"Correlation between abnormal GSK3\u03b2, \u03b2 amyloid, total tau, p-tau 181 levels and neuropsychological assessment total scores in CKD patients with cognitive dysfunction: impact of rHuEPO therapy","volume":"69","author":"Vinothkumar","year":"2019","journal-title":"J Clin Neurosci"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0059","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13470","article-title":"GSK-3\u03b2 activation mediates apolipoprotein E4-associated cognitive impairment in type 2 diabetes mellitus: a multicenter, cross-sectional study","volume":"16","author":"Gao","year":"2024","journal-title":"J Diabetes"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30487-6","article-title":"IL-1\u03b2, IL-6, TNF-\u03b1 and CRP in elderly patients with depression or Alzheimer\u2019s disease: systematic review and meta-analysis","volume":"8","author":"Ng","year":"2018","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.retram.2026.103568_bib0061","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","article-title":"Cholinergic system during the progression of Alzheimer\u2019s disease: therapeutic implications","volume":"8","author":"Mufson","year":"2008","journal-title":"Expert Rev Neurother"},{"issue":"1\u20132","key":"10.1016\/j.retram.2026.103568_bib0062","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0006-8993(98)00579-4","article-title":"Long term changes in brain cholinergic markers and nerve growth factor levels after partial immunolesion","volume":"801","author":"Gu","year":"1998","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.retram.2026.103568_bib0063","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12882-015-0068-7","article-title":"Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease","volume":"16","author":"Lee","year":"2015","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1016\/j.retram.2026.103568_bib0064","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.3390\/ijms24076518","article-title":"Inflammatory processes in alzheimer\u2019s disease\u2014Pathomechanism, diagnosis and treatment: a review","volume":"24","author":"Twarowski","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.retram.2026.103568_bib0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ckj\/sfv074","article-title":"Cholinergic anti-inflammatory pathway activity in dialysis patients: a role for neuroimmunomodulation?","volume":"8","author":"Hilderman","year":"2015","journal-title":"Clin Kidney J"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862600005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862600005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:53:08Z","timestamp":1775065988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245231862600005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S245231862600005X"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103568","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unusual expression of peripheral blood Alzheimer\u2019s markers, inflammatory cytokines, and cholinergic biomarkers in chronic kidney disease patients with cognitive dysfunction: Therapeutic impact of recombinant human erythropoietin (rHuEPO)","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103568"}}